SCHEMBL25367357

SCHEMBL25367357

COc1cc2cc[nH]c(=O)c2cc1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
TDP1 Q9NUW8 2/20 0.42
LMNA P02545 3/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
ROCK1 Q13464 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
BRCA1 P38398 1/20 0.39
HNF4A P41235 1/20 0.39
HIF1A Q16665 1/20 0.39
MCL1 Q07820 1/20 0.39
MAP2K1 Q02750 1/20 0.38
CHEK1 O14757 1/20 0.38
TUBB4A P04350 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3951034 0.81 ROCK1 (0.46) ALDH1A1ROCK1SMN1; SMN2MCL1MAP2K1
SCHEMBL29507005 0.81 TLR8 (0.48) ALDH1A1TDP1LMNAPDGFRBPDGFRA
SCHEMBL26683823 0.81 TLR8 (0.48) ALDH1A1TDP1LMNAPDGFRBPDGFRA
SCHEMBL25369624 0.81 ALDH1A1 (0.50) ALDH1A1LMNAROCK1CYP1A2MAPT
SCHEMBL17801460 0.78 ALDH1A1 (0.50) ALDH1A1TDP1LMNACYP1A2HIF1A
SCHEMBL25368500 0.78 ALDH1A1 (0.50) ALDH1A1ROCK1MAP2K1CHEK1
SCHEMBL28899200 0.78 TYMS (0.52) ALDH1A1TDP1LMNACYP1A2MAPT
SCHEMBL1204984 0.77 ROCK1 (0.55) ALDH1A1ROCK1MAP2K1TUBB4ATUBB
SCHEMBL1536435 0.76 ROCK1 (0.42) LMNAROCK1MAP2K1HTT
SCHEMBL1536538 0.76 MAP2K1 (0.56) ROCK1MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154140-A1 ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF Sunnybrook Research Institute (CA) 2025-05-15 US disclosed
EP-4479383-A1 ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF Sunnybrook Research Institute (CA) 2024-12-25 EP disclosed
CN-119013259-A Isoquinoline derivatives as inhibitors of BAX and/or BAK, compositions and uses thereof 森尼布鲁克研究院 2024-11-22 CN disclosed
WO-2023155019-A1 ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF Sunnybrook Research Institute (CA) 2023-08-24 WO disclosed
CN-110294742-B Fused ring ASK1 inhibitor and application thereof 山东轩竹医药科技有限公司 2023-01-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154140-A1 ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF BAK1, BAX, BCL2 ALDH1A1 3801/4885TDP1 214/4885LMNA 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.